MAIA Biotechnology, Inc. – Q3 2025 Summary for Investors
Financial Performance and Position - Net Loss: The company reported a net loss of $8.9 million for Q3 2025 (vs. $2.7 million in Q3 2024), and a net loss of $18.8 million for the nine months ended September 30, 2025 (vs. $19.7 million in 2024). - Operating Expenses: R&D expenses for Q3 2025 increased 138% to $6.4 million (vs. $2.7 million in Q3 2024). For the nine months, R&D expenses were $12.7 million, up 80% from $7.0 million in the prior year period. G&A expenses rose 97% in the quarter to $3.0 million and 48% YTD to $7.3 million. - Cash Position: As of September 30, 2025, cash totaled $10.9 million, up from $9.6 million at December 31, 2024. - Liquidity: Net cash used in operating activities totaled $11.8 million for the nine months (in line with $11.8 million in 2024). Cash provided by financing activities was $13.1 million. - Stockholders' Equity: Equity dropped sharply to $41,670 as of September 30, 2025, down from $3.6 million at year-end 2024, due to continued losses. - Accumulated Deficit: Stood at $106.0 million on September 30, 2025 (from $87.2 million at 2024 year-end). - Shares Outstanding: 37,032,307 as of November 7, 2025.
Capital Raising/Financing Activities - ATM and Private Placements: The company raised funds via At-The-Market offerings ($6.8 million) and multiple private placement rounds (over $5.9 million across four rounds in 2025). - Warrants: As of September 30, 2025, there were 9,702,689 warrants outstanding (weighted average exercise price: $2.06), up from 5,442,246 a year earlier. - Stock Options: 12,129,624 options were outstanding at September 30, 2025 (weighted average exercise price: $2.24). - Subsequent Events: Additional shares and warrants issued in October 2025.
Operations and Developments - Pipeline: Focused on developing telomere-targeting anti-cancer drugs (notably ateganosine, THIO), with expansion in clinical trials including Phase 2 and plans for a pivotal Phase 3 (THIO-104) in NSCLC. - Collaborations: Clinical supply agreements with BeOne Medicines and Roche; NIH SBIR grant in September 2025; intellectual property advances including new patents. - FDA Fast Track: Received for ateganosine/THIO in HCC in July 2025.
Risks and Uncertainties - Going Concern: The company highlighted risks regarding ongoing negative cash flows, recurring losses, and the necessity to raise additional funds to sustain operations and advance clinical programs. - Digital Assets Strategy: In October 2025, MAIA adopted a Digital Asset Treasury Plan (DATP) permitting Bitcoin/ETH investments, introducing risks such as regulatory uncertainty, price volatility, liquidity, risk of loss due to cyberattacks, classification as an investment company, and limited staking history. - Concentration and Off-Balance Sheet Risks: No material off-balance sheet risks.
Legal and Regulatory - Litigation: No material litigation outstanding. - New Accounting Rules: Not expected to have a material near-term impact.
Key Metrics - Total Assets: $11.8 million (up from $10.2 million at year-end 2024). - Current Liabilities: $10.0 million, including $3.2 million accounts payable and $6.8 million accrued expenses (notably $2.9 million R&D costs and $2.1 million held in escrow). - Warrant Liability: $1.7 million (down from $2.7 million at end of 2024).
Summary/Outlook MAIA Biotechnology continues to advance its clinical programs, raising sufficient funds to support YTD operations but faces short-term liquidity concerns and relies on further capital raises for sustainability. Recent strategic moves, such as the DATP, add complexity to the risk profile. Investors should closely monitor dilution, ongoing operating losses, future clinical milestone progress, and execution of the new digital asset strategy.
Visit Publicview AI to search and analyze millions of SEC filings using AI.
